Clinical trials: Heartburn
Pompe Disease, Glycogen Storage Disease Type II
An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease
The purpose of this study was to evaluate the efficacy, clinical benefits and safety of a prophylactic immunomodulatory regimen given prior to first treatment with alglucosidase alfa (Myozyme®) in patients with infantile-onset…
- Trial name
- NCT00701129
- Testing
- Alglucosidase Alfa, Methotrexate, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Genzyme, a Sanofi Company
Reflux, Heartburn
Evaluation Study of a Management Strategy for Gastroesophageal Reflux Disease (GERD)
The aim of this project is to compare the GERD clinical outcomes in patients where a structured pathway using the GerdQ questionnaire is implemented compared with the clinical outcomes of those treated without this…
- Conditions
- Reflux, Heartburn, Regurgitation, Esophagitis
- Trial name
- NCT00842387
- Where
- 66 sites in Austria, Italy and 3 more
- Volunteers
- 2,370 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease, Esophageal Cancer
Decision Aid for Gastroesophageal Reflux Disease Management
The study is to test a decision aid that is designed to help patients make decision regarding management of their gastroesophageal reflux disease (GERD).
- Conditions
- Gastroesophageal Reflux Disease, Esophageal Cancer, Barrett's Esophagus
- Trial name
- NCT01641887
- Testing
- Decision Aid
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Heartburn, Gastroesophageal Reflux Disease
Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)
A double-blind study comparing Esomeprazole Magnesium 40 mg once daily and Lansoprazole 30 mg twice daily to control the symptoms in patients with gastroesophageal reflux disease (GERD) with continued heartburn symptoms with a…
- Trial name
- NCT00637845
- Testing
- Esomeprazole Magnesium, Lansoprazole
- Volunteers
- 248 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn
The purpose of this study is to assess the efficacy and safety of daily treatment with Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily [QD]) compared to placebo QD in relief of daytime and nighttime heartburn…
- Trial name
- NCT00251745
- Testing
- Dexlansoprazole MR
- Where
- 95 sites in United States
- Volunteers
- 908 people
- Sponsor
- Takeda
GERD, Acid Reflux, Treatment
Potassium Competitive Acid Blocker (PCAB) Test-Guided vs Physiologic Test-Guided Treatment in Patients With Typical Reflux Symptoms
The goal of this clinical trial is to learn if a short course of a potassium-competitive acid blocker (PCAB) test can guide treatment of adults with typical reflux symptoms as effectively as standard physiologic testing with…
- Trial name
- NCT07707011
- Testing
- PCAB-test guided
- Where
- Thailand
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Gastroesophageal Reflux Disease
Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease
The purpose of this study is to assess the efficacy and safety of Dexlansoprazole modified release (MR) (30 mg once daily [QD] or 60 mg QD) compared to placebo in relief of daytime and nighttime heartburn over 4 weeks in subjects…
- Trial name
- NCT00321984
- Testing
- Dexlansoprazole MR
- Where
- 153 sites in United States
- Volunteers
- 947 people
- Sponsor
- Takeda
Gastrointestinal Discomfort
Effects of Mucosave® on Gastrointestinal Discomfort
Gastrointestinal (GI) discomfort, which often includes gastroesophageal reflux disease (GERD) is a common disorder in healthy adults affecting 20% of people particularly women.
- Trial name
- NCT04119817
- Testing
- Mucosave® capsules
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico "G. Martino"
Gastroesophageal Reflux
ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)
The purpose of this study is to evaluate the effect of ADX10059 in patients with gastroesophageal reflux disease who are partial responders to proton pump inhibitors
- Trial name
- NCT00810485
- Testing
- ADX10059
- Where
- 40 sites in United States, France and 3 more
- Volunteers
- 298 people
- Sponsor
- Addex Pharma S.A.
Gastroesophageal Reflux Disease, GERD
What is the Predictive Value of the Reflux Impact Scale
Gastric distress is a common phenomenon in our society. Heartburn and regurgitation occur daily in about 7% of the adult population,weekly 14-20% pf the adults and monthly in 34-44% of adults.
- Conditions
- Gastroesophageal Reflux Disease, GERD, Heartburn, Acid Regurgitation
- Trial name
- PREDICT (NCT00536328)
- Volunteers
- 938 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Radiofrequency Energy Delivery for Gastroesophageal Reflux Disease
This study is to evaluate the safety and efficacy of radiofrequency energy procedure for Gastro-esophageal reflux disease (GERD) based on changes of symptoms, medication esophagitis grade, esophageal acid exposure and lower…
- Trial name
- NCT03223116
- Testing
- Radiofrequency delivery
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Changhai Hospital
Gastroesophageal Reflux Disease, Heartburn
Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI
This study is being carried out to see whether AZD3355 is an effective treatment as an add-on to PPI therapy in patients with Gastroesophageal Reflux Disease (GERD) with a partial response to PPI and to compare this with Proton…
- Conditions
- Gastroesophageal Reflux Disease, Heartburn, Regurgitation
- Trial name
- NCT01005251
- Testing
- lesogaberan (AZD3355)
- Where
- United States
- Volunteers
- 661 people
- Sponsor
- AstraZeneca
Symptomatic Gastroespohageal Reflux Disease
A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD)
Gastroesophageal Reflux Disease (GERD) is a common disorder caused by the reflux of gastric (stomach) acid into the esophagus. The exposure of the lining of the esophagus to the acid will cause damage to the esophagus over time.
- Trial name
- NCT00149851
- Testing
- Tegaserod
- Where
- United States
- Volunteers
- 832 people
- Sponsor
- Novartis
Gastroesophageal Reflux Disease, GERD
Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD)
The objective of this study is to evaluate the efficacy, acceptability, and safety of Axid Oral Solution versus placebo in the treatment of gastroesophageal reflux disease (GERD) in infants age 30 days up to 1 year.
- Conditions
- Gastroesophageal Reflux Disease, GERD, Heartburn
- Trial name
- NCT00373334
- Testing
- nizatidine (axid)
- Where
- 26 sites in United States
- Volunteers
- 138 people
- Sponsor
- Braintree Laboratories
Frequent Heartburn
A Study to Investigate Use Patterns and Safety in Simulated Actual Over-the-counter (OTC) Use of Rabeprazole Sodium for the Treatment of Heartburn Symptoms
This is a multi-center, open-label, all-comers OTC actual use study in pharmacy sites where the principal investigator will be a pharmacist.
- Trial name
- NCT01286194
- Testing
- Rabeprazole sodium
- Where
- 33 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Eisai Inc.
Anemia, Constipation
Questionnaire to Assess Gastrointestinal Symptoms of Oral Iron.
Oral iron supplementation is often associated with rapid onset of gastrointestinal side-effects. The aim of this study was to develop and trial a short, simple questionnaire to capture these early side-effects and to determine…
- Conditions
- Anemia, Constipation, Diarrhea, Abdominal Pain
- Trial name
- NCT02146053
- Testing
- ferrous sulfate
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Medical Research Council
Heartburn, Acid Regurgitation
Fermented Soy and Heartburn Symptom Relief
Heartburn is as common gastrointestinal symptom experienced by otherwise healthy adults and typically manifests as a painful burning sensation in the upper abdomen or in the chest.
- Trial name
- NCT03867591
- Testing
- Gastro-AD®
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- University of Florida
Heartburn in Pregnancy
Alginate-based Reflux Suppressant and Magnesium-aluminium Antacid Gel for Treatment of Heartburn in Pregnancy
This study evaluates the efficacy of alginate-based reflux suppressant and magnesium-aluminium antacid gel for treatment of heartburn in pregnancy.
- Trial name
- NCT02470117
- Testing
- Alginate-based reflux suppressant, magnesium-aluminium antacid gel
- Where
- Thailand
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
Gastroesophageal Reflux Disease (GERD)
Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients
The purpose of this study is to estimate the effect of AZD3355 as an add-on treatment to a Proton Pump Inhibitor (PPI) on Gastroesophageal reflux disease (GERD) symptoms in patients with an incomplete response to PPI treatment.
- Trial name
- NCT00394472
- Testing
- AZD3355
- Where
- 38 sites in Australia, Belgium and 6 more
- Volunteers
- 244 people
- Sponsor
- AstraZeneca
Hypergastrinaemia
Effect of Single Doses of YF476 on Stomach Acidity
The objective of the study was to assess the effect of a range of single oral doses of YF476 on pentagastrin-induced gastric acid output in healthy volunteers
- Trial name
- NCT01601418
- Testing
- YF476
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.